Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768594 | 0.92 | MEN1 (0.54) | MEN1KMT2ACYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL6765995 | 0.91 | MEN1 (0.62) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6769206 | 0.91 | KMT2A (0.52) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6765928 | 0.91 | KMT2A (0.55) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6768955 | 0.90 | MEN1 (0.51) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4863973 | 0.90 | MEN1 (0.51) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6769248 | 0.89 | MEN1 (0.51) | MEN1KMT2ACYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL6765474 | 0.89 | KMT2A (0.53) | MEN1KMT2ACYP3A4CYP2D6ALDH1A1 | |
| SCHEMBL4865691 | 0.88 | MEN1 (0.52) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6770397 | 0.88 | MEN1 (0.52) | MEN1KMT2ACYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | claimed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | claimed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | claimed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | claimed |
| US-6677336-B2 | PARTIAL FATTY ACID OXIDATION INHIBITORS; PROTECT SKELETAL MUSCLES AGAINST DAMAGE RESULTING FROM TRAUMA OR SYSTEMIC DISEASES, TREAT SHOCK CONDITIONS, PRESERVE DONOR TISSUE AND ORGANS USED IN TRANSPLANTS | CV THERAPEUTICS, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020016463-A1 | Substituted piperazine compounds | CV THERAPEUTICS, INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016463-A1 | Substituted piperazine compounds | ATP2A1, CPT1B, TNNC1 | MEN1 4696/4885KMT2A 4291/4885CYP3A4 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.